Candesartan in renal artery stenosis (CARLAS)

Completed

• Conditions: Renal artery stenosis; Circulatory System

• Registration Number: ISRCTN35143689
• Lead Sponsor: AstraZeneca (Sweden)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-12-18
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Blood pressure above 140 mmHg/90 mmHg
2. Confirmation of renal artery stenosis by either duplex ultrasonography, CT-angiography or MR-angiography

Exclusion Criteria

1. Renal size <7.5 cm at the stenotic side
2. Age >80 years
3. Pregnancy or nursing mother
4. Terminal renal failure (Glomerular Filtration Rate [GFR] <15 ml/min)
5. Treatment with Angiotensin-Converting Enzyme (ACE) inhibitors or angiotensin receptor blockers
6. Renovascular hypertension of other etiology than atherosclerosis or Flow-Mediated Dilation (FMD)
7. Chronic glomerular disease with urinary albumin excretion (in mg/24h) (tU-alb) >1g/day
8. Diabetic nephropathy with tU-alb >0.3 g/day
9. Contraindication for renal angiography/PTRA (eg. serious contrast allergy)
10. Other forms of secondary hypertension
11. Serious malignant disease
12. Treatment with immune-modulating medications eg. cyclosporin and oral steroids

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Renal function measured by EDTA-clearance and frequency of restenosis 3 years after PTRA.

Secondary Outcome Measures

Name	Time	Method
Cardiovascular events 3 years after PTRA.